David Rutley, MP for Macclesfield, has welcomed the news that AstraZeneca and Manchester Science Parks (MSP) have exchanged contracts on the purchase of the Alderley Park site.
The sale is an important step in establishing a world class bioscience facility at Alderley Park, in line with the Alderley Park Taskforce’s vision for the site.
David, a member of the Alderley Park Taskforce, said, “This is a vital milestone in establishing a sustainable future for the Alderley Park site. It builds on the site’s rich heritage of research and innovation, and helps underpin a strong life sciences strategy for north east Cheshire. This is critical, not just for the North West, but for the UK life sciences sector. I look forward to working with MSP to realise the site’s potential in the months ahead as a member of the Alderley Park Taskforce.”
This is further good news for north east Cheshire as it builds on the announcement in November 2013 of a £120 million investment by AstraZeneca to upgrade the production of Zolodex at its neighbouring Macclesfield site.